BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:nChroma Bio\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies nChroma Bio\, Inc.'s drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07200193-10234@assetmemo.bio
DTSTAMP:20261121T010135Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:CRMA-1001: Phase 1/2 readout est. (NCT07200193)
DESCRIPTION:CRMA-1001\, phase 1/2\, Chronic Hepatitis B.\nStudy: A Phase 1/
 2\, Open-Label\, Single and Multiple Ascending Dose Study of CRMA-1001 in 
 Adults With Chronic Hepatitis B\nEstimated primary completion: February 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/crma-1001#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07200193
URL:https://assetmemo.bio/drug/crma-1001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
